[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained.
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


2. Huang R, Jaffer S: Imprint cytology of metastatic sialoblastoma. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sialoblastoma is a rare, aggressive and potentially malignant perinatal/congenital tumor that recapitulates the developing salivary gland.
  • Imprint smears and frozen section of the mass were diagnostic of metastatic sialoblastoma.
  • The differential diagnoses include neoplasms composed of either basaloid cells and/or admixed hyaline matrix material and included pleomorphic adenoma, basal cell adenoma and adenoid cystic carcinoma.
  • All these neoplasms affect patients in the first 2 years of life, whereas sialoblastoma usually occurs in the first 2 decades of life.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Disease Progression. Epithelial Cells / pathology. Female. Humans. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Parotid Gland / pathology. Parotid Gland / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674095.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ: The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials; 2010 Apr 21;11:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma is the commonest human cancer.
  • To compare excisional surgery with imiquimod cream for nodular or superficial basal cell carcinoma in low risk sites, with respect to 3 year clinical clearance, cost-effectiveness and cosmetic results.
  • METHODS/DESIGN: Five hundred participants with low risk nodular or superficial basal cell carcinoma will be recruited from hospitals to this multi-centre, randomised, parallel group, controlled phase III trial.
  • Treatment in the imiquimod group is for 6 weeks for superficial basal cell carcinoma and 12 weeks for nodular basal cell carcinoma.
  • Primary outcome variable: the proportion of participants with clinical evidence of success (no recurrence) at 3 years.
  • Secondary outcomes include: i) clinical success at 1, 2 and 5 years, ii) time to first recurrence, iii) cosmetic appearance of lesion site after treatment, iv) level of pain, and v) cost-effectiveness.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Administration, Cutaneous. Cost-Benefit Analysis. Drug Costs. Female. Genotype. Health Care Costs. Humans. Male. Ointments. Patient Satisfaction. Phenotype. Polymorphism, Genetic. Prospective Studies. Recurrence. Research Design. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):840-5 [19438849.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Am J Epidemiol. 2004 Apr 1;159(7):702-6 [15033648.001]
  • [Cites] J Dermatol Surg Oncol. 1986 Aug;12(8):860-5 [3734238.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] Br J Dermatol. 1994 Dec;131(6):914-5 [7857854.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):593-6 [9158412.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1255-9 [10522675.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2105-8 [17640064.001]
  • [Cites] J Clin Epidemiol. 2009 May;62(5):464-75 [19348971.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • (PMID = 20409337.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN48755084; ClinicalTrials.gov/ NCT00066872
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; P1QW714R7M / imiquimod
  • [Other-IDs] NLM/ PMC2877028
  •  go-up   go-down


Advertisement
4. Qing Y, Cen Y, Wang H, Liu Y: [Surgical treatment of scalp malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Jan;22(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of scalp malignant tumor].
  • OBJECTIVE: To investigate the effects of different surgical methods in treating scalp malignant tumors.
  • METHODS: From January 1995 to September 2004, 70 patients with scalp malignant tumor were treated with different surgical methods.
  • There were 31 cases of basal cell carcinoma, 24 cases of squamous carcinoma, 8 cases of melanocarcinoma, 4 cases of fibrous sarcoma, 2 cases of liposarcoma, and 1 case of vasculosarcoma.
  • RESULTS: Of 70 cases, 67 skin flaps survived and incision healed by first intention; 2 flaps necrosed at distal part (< 1 cm) and healed by second intention after dressing change; 1 flap infected and was treated with symptomatic medication.
  • All the donor sites healed by first intention.
  • Fifty-five patients were followed up for 1 to 5 years and 5 cases had tumor recurrence.
  • In patients receiving skin transplantation, 1 case of squamous carcinoma and 1 case of fibrous sarcoma relapsed after 1 year and 2.5 years respectively and were given radical resection and skin flap grafting; in patients receiving skin flap grafting, 1 case of vasculosarcoma and 1 case of squamous carcinoma relapsed after 6 months and 3 months respectively, and gave up treatment; 1 case of fibrous sarcoma relapsed after 2 years and was given radical resection and skin flap grafting.
  • The other cases survived and had no tumor recurrence.
  • CONCLUSION: Scalp malignant tumors should be diagnosised and treated as early as possible.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Scalp. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361240.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA: Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Ann Intern Med; 2009 Jan 6;150(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.
  • OBJECTIVE: To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans.
  • PARTICIPANTS: 1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004.
  • MEASUREMENTS: Time to first occurrence of keratinocyte carcinoma on the face or ears.
  • In the propensity score-matched analysis, statin use at randomization was not associated with keratinocyte carcinoma (rate ratio, 0.92 [95% CI, 0.73 to 1.16]), a finding that was consistent with the estimates derived from the Cox proportional hazards regression (rate ratio, 0.84 [CI, 0.70 to 1.02]).
  • CONCLUSION: These data show no conclusive or consistent relationship between long-term statin use and risk for keratinocyte carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Jun 21;295(23):2721; author reply 2721-2 [16788124.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):549-59 [16899775.001]
  • [Cites] Int J Clin Pract. 2006 Sep;60(9):1028-34 [16939542.001]
  • [Cites] Am J Cardiol. 2006 Oct 1;98(7):923-8 [16996875.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Circulation. 2007 Jan 2;115(1):27-33 [17179016.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):32-40 [17202111.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):213-9 [17235211.001]
  • [Cites] Dement Geriatr Cogn Disord. 2007;23(3):194-201 [17259710.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):279-84 [17482716.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):393-402 [17681160.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2323-7 [17522705.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94 [18199714.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):825-37 [18371146.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):767-74 [18322813.001]
  • [Cites] JAMA. 2000 Jun 28;283(24):3211-6 [10866868.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2363-8 [10927735.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Med Care. 2003 Jun;41(6):761-74 [12773842.001]
  • [Cites] Pharmacotherapy. 2003 Jun;23(6):726-30 [12820814.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):146-52 [14744837.001]
  • [Cites] Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S [15095548.001]
  • [Cites] Am J Cardiol. 2004 May 1;93(9):1124-9 [15110204.001]
  • [Cites] Lancet. 2004 May 15;363(9421):1607-8 [15145635.001]
  • [Cites] Lancet Neurol. 2004 Jun;3(6):369-71 [15157852.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Arch Dermatol. 1991 Aug;127(8):1194-7 [1863078.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1286-90 [8215493.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):164-9 [7857112.001]
  • [Cites] J R Soc Med. 1997 Jul;90(7):371-4 [9290417.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):643-7 [15578694.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1425-35 [15755765.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 [15651087.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003697 [16235336.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2437-45 [16287954.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Oncologist. 2006 Mar;11(3):306-15 [16549815.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1149-56 [16624967.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2720-1; author reply 2721-2 [16788122.001]
  • (PMID = 19124815.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00007631
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106592; United States / NCI NIH HHS / CA / R25CA087972; United States / NCI NIH HHS / CA / R01CA106807; United States / NIAMS NIH HHS / AR / R01 AR049342; United States / AHRQ HHS / HS / 5T32HS000011-21; United States / NCI NIH HHS / CA / R01 CA106807; United States / NCI NIH HHS / CA / R25 CA087972; United States / NCI NIH HHS / CA / R01CA106592; United States / AHRQ HHS / HS / T32 HS000011; United States / NIAMS NIH HHS / AR / R01AR49342
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS507348; NLM/ PMC3771656
  •  go-up   go-down


6. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM: Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol; 2001 Mar;137(3):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established.
  • We propose that delta-ALA PDT be considered as a first-line therapy for large and/or multiple areas of Bowen disease and superficial BCCs.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary / drug therapy. Photosensitizing Agents / therapeutic use

  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255332.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


7. Xu S, Wang X, Xu W, Xia Y, Zhang C: Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin Med J (Engl); 2002 Aug;115(8):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eighty-eight patients, including 34 cases of basal cell carcinoma (BCC), 32 cases of squamous cell carcinoma (SCC), two cases of basal-squamous cell carcinoma (BSCC), one case of verrucuous carcinoma, nine cases of Bowen disease, two cases Paget disease of the nipple and eight cases of extramammary Paget disease, were treated by the partial differential alpha-aminolevulinic acid induced photodynamic therapy first in China from 1997 to 2000.
  • The recurrence rates were 11% (4/34) for BCC, and 22% (7/32) for SCC by following up 1-3 years after the therapy.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215278.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


8. Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS: Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer; 2010;62(8):1058-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence.
  • Using data from a randomized, double blind, study of the efficacy of retinol or isotretinoin vs. placebo on recurrence of nonmelanoma skin cancer in high-risk subjects, a reanalysis of the original intent to treat analysis was performed in a dose-response format.
  • Cox proportional hazards models describe the relationship between dose quartiles of isotretinoin and retinol use and time to first occurrence of squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) in crude and adjusted models.
  • Neither the isotretinoin nor retinol models showed any significance at any quartile for reduction in first BCC or SCC occurrence.
  • Crude and adjusted retinol models show a statistically significant increase in risk of developing an SCC in the first quartile, whereas only the crude model shows a statistically significant increase in risk in the first quartile of the isotretinoin model.
  • For retinol and SCC, hazard ratios (HRs) for the first quartile were as follows: HR = 2.92, 95% confidence interval (CI) = 1.67-5.10 crude; HR = 1.95, 95% CI = 1.00-3.80 adjusted.
  • For isotretinoin and SCC, HRs for the first quartile were as follows: HR = 2.38, 95% CI = 1.35-4.19 crude; HR = 1.69, 95% CI = 0.87-3.31 adjusted.
  • These analyses confirm the results of the original intent to treat analyses and raise an interesting question related to the potential for increased risk for patients in the first quartile of retinol dose.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 2000 Jun;21(3):241-3 [10822121.001]
  • [Cites] Br J Dermatol. 1999 Apr;140(4):656-60 [10233316.001]
  • [Cites] Nutrition. 2000 Nov-Dec;16(11-12):1084-9 [11118831.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] J Am Acad Dermatol. 2003 Oct;49(4):644-50 [14512910.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1297-305 [15138569.001]
  • [Cites] Br J Cancer. 1970 Jun;24(2):235-52 [5451567.001]
  • [Cites] Agents Actions. 1970 Aug;1(4):172-5 [5520364.001]
  • [Cites] Nutr Rev. 1977 Apr;35(4):65-9 [854240.001]
  • [Cites] Biochim Biophys Acta. 1980 Mar 12;605(1):33-91 [6989400.001]
  • [Cites] J Natl Cancer Inst. 1981 Jan;66(1):7-16 [6935468.001]
  • [Cites] Gynecol Oncol. 1981 Oct;12(2 Pt 2):S331-40 [6946954.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Nutr Cancer. 1983;5(2):96-106 [6359074.001]
  • [Cites] J Clin Oncol. 1983 Jun;1(6):394-9 [6668507.001]
  • [Cites] Neoplasma. 1984;31(5):615-8 [6594593.001]
  • [Cites] Br J Cancer. 1986 Dec;54(6):957-61 [3801291.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50 [15572756.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1596-607 [16030089.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):441-50 [16595780.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):499-502 [3477106.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):795-801 [2202902.001]
  • [Cites] Stat Med. 1991 Oct;10(10):1595-605 [1947515.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] Nutr Cancer. 1992;18(3):237-44 [1296197.001]
  • [Cites] Clin Pharmacol Ther. 1995 Jan;57(1):6-15 [7828382.001]
  • [Cites] J Clin Epidemiol. 1994 Aug;47(8):829-36 [7730885.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Biometrics. 1996 Sep;52(3):1002-17 [8805765.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):203-5 [9103292.001]
  • [Cites] J Clin Pharmacol. 1997 Aug;37(8):667-72 [9378838.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] J Eur Acad Dermatol Venereol. 1998 Jan;10(1):42-7 [9552756.001]
  • [Cites] Pharmacol Rev. 1998 Jun;50(2):315-33 [9647871.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1271-9 [10874003.001]
  • (PMID = 21058193.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / CA-27502; United States / NCI NIH HHS / CA / CA-34256
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; EH28UP18IF / Isotretinoin
  • [Other-IDs] NLM/ NIHMS583867; NLM/ PMC4104190
  •  go-up   go-down


9. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM: Bladder cancer stem cells. Curr Stem Cell Res Ther; 2010 Dec;5(4):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cells are undifferentiated cells that renew themselves while simultaneously producing differentiated tissue- or organspecific cells through asymmetric cell division.
  • The appreciation of the importance of stem cells in normal tissue biology has prompted the idea that cancers may also develop from a progenitor pool (the "cancer stem cell (CSC) hypothesis"), and this idea is gaining increasing acceptance among scientists.
  • CSCs are sub-populations of cancer cells responsible for tumor initiation, differentiation, recurrence, metastasis, and drug resistance.
  • First identified in the hematopoietic system, CSCs have also been discovered in solid tumors of the breast, colon, pancreas, and brain.
  • Recently, the tissue-specific stem cells of the normal urothelium have been proposed to reside in the basal layer, and investigators have isolated phenotypically similar populations of cells from urothelial cancer cell lines and primary tumors.
  • Herein, we review the CSC hypothesis and apply it to explain the development of the two different types of bladder cancer: noninvasive ("superficial") carcinoma and invasive carcinoma.
  • [MeSH-major] Carcinoma / pathology. Neoplastic Stem Cells / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Disease Progression. Humans. Models, Biological. Neoplasm Invasiveness. Organ Specificity. Stem Cell Niche

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20955163.001).
  • [ISSN] 2212-3946
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Sidoroff A: [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review]. Hautarzt; 2007 Jul;58(7):577-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For Bowen disease and superficial basal cell carcinoma, PDT can be regarded as the first-line non-invasive treatment.
  • In nodular basal cell carcinoma, effectiveness for lesions up to a thickness of 2 mm is well documented.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy. Sunlight / adverse effects
  • [MeSH-minor] Cryotherapy. Evidence-Based Medicine. Humans. Multicenter Studies as Topic. Neoplasm Recurrence, Local / drug therapy. Patient Acceptance of Health Care. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cosmet Laser Ther. 2003 Jun;5(2):107-10 [12850802.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S19-23 [12060513.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Acta Derm Venereol. 2005;85(6):483-90 [16396794.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Arch Dermatol Res. 1996 Sep;288(10):561-4 [8919036.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):767-72 [11069454.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2 Suppl):17-25 [16485877.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10):1313-20 [14568836.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 17522831.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


11. Banerjee S: Cutaneous manifestations in renal failure patients: a case series. Indian J Dermatol Venereol Leprol; 2007 Mar-Apr;73(2):106-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous involvement in renal disease is due to a host of factors ranging from metabolic disturbances to immunosuppressive drugs.
  • Our first case had cutaneous cryptococcosis where skin lesions gave a clue to the diagnosis of altered sensorium and underlying meningitis.
  • The second case initially presented with florid warts and was treated successfully but later presented with an explosive recurrence of skin lesions due to malignant transformation.
  • Our third case had basal cell carcinoma over the presternal region that was successfully treated with liquid nitrogen cryotherapy.
  • The last case had cutaneous manifestations of drug therapy because of heparin infusion.
  • To conclude, cutaneous manifestations in patients with renal failure are varied and a high degree of suspicion is needed for early diagnosis and aggressive treatment to effectively combat mortality and morbidity.
  • [MeSH-minor] Acute Kidney Injury / complications. Adolescent. Adult. Carcinoma, Basal Cell / etiology. Condylomata Acuminata / etiology. Cryptococcosis / etiology. Dermatomycoses / etiology. Female. Humans. Kidney Failure, Chronic / complications. Male. Middle Aged. Parapsoriasis / chemically induced. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456917.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down






Advertisement